Václav H.
- Country
- Czechia
- Department
- N/A
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- Evaluation of the Efficacy and Safety of Obeticholic Acid and Bezafibrate in Patients with Primary Biliary Cholangitis Unresponsive or Intolerant to Ursodeoxycholic Acid
- Evaluation of Semaglutide in Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages 2 or 3: A Randomized, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 113 of 240 partner sites.
Specializations
Liver Disease Management
The investigator specializes in treating non-alcoholic steatohepatitis (NASH) and liver cirrhosis, focusing on innovative therapeutic approaches for these chronic liver conditions.
- NASH with liver fibrosis
- Cirrhosis complications
- Fluid retention management
Expertise extends to evaluating novel treatments for improving liver histology and preventing liver-related clinical events.
Cholestatic Disorders
Dedicated to advancing treatment options for Primary Biliary Cholangitis (PBC) and related cholestatic conditions, with particular attention to managing disease progression.
- PBC therapeutic interventions
- Cholestatic pruritus treatment
- Bile acid homeostasis
Focuses on evaluating long-term safety and efficacy of various therapeutic combinations for PBC management.
Hepatic Biomarkers
Investigates biochemical markers and therapeutic responses in liver diseases, particularly focusing on alkaline phosphatase normalization and liver enzyme profiles.
- Liver enzyme monitoring
- Disease progression markers
- Therapeutic response assessment
Expertise in evaluating biochemical disease markers and biomarkers of bile acid synthesis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.